arthyperАртериальная гипертензия"Arterial’naya Gipertenziya" ("Arterial Hypertension")1607-419X2411-8524Antihypertensive League10.18705/1607-419X-2003-9-2-51-54arthyper-874Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESТерапия акарбозой как профилактика множественных сердечно-сосудистых факторов риска метаболического сивдромаAcarbose therapy as prevention of multiple cardiovascular risk factors of metabolic syndromeМычкаВ. Б.MychkaV. B.noemail@neicon.ruБогиеваР. М.BogiyevaR. M.noemail@neicon.ruМамырбаеваК. М.MamyrbayevaK. M.noemail@neicon.ruЧазоваИ. Е.ChazovaI. Ye.noemail@neicon.ruИнститут клинической кардиологии им. А.Л.Мясникова; Российский кардиологический научно-производственный комплекс Минздрава РФРоссия200328042003925154Copyright © Мычка В.Б., Богиева Р.М., Мамырбаева К.М., Чазова И.Е., 20032003Мычка В.Б., Богиева Р.М., Мамырбаева К.М., Чазова И.Е.Mychka V.B., Bogiyeva R.M., Mamyrbayeva K.M., Chazova I.Y.This work is licensed under a Creative Commons Attribution 4.0 License.https://htn.almazovcentre.ru/jour/article/view/874

Метаболический синдром - это состояние, которое предшествует развитию атеросклероза, сахарного диабета типа 2, артериальной гипертонии (AT) Своевременное адекватное лечение может предотвратить развитие и прогрессирование этих заболеваний, которые являются основными причинами повышенной смертности населения Предпочтением у больных с высоким сердечно-сосудистым риском должны пользоваться лекарственные препараты периферического действия Одним из таких препаратов является акарбоза, которая препятствует всасыванию углеводов в тонком кишечнике Результаты нашего опыта применения акарбозы показали ее высокую эффективность На фоне монотерапии акарбозой достоверно снижались масса тела, постпрандиальный уровень глюкозы, гликированный гемоглобин и артериальное давление Акарбоза может применяться в качестве монотерапии у больных с метаболическим синдромом и мягкой AT

The metabolic syndrome is a state that precedes the development of atherosclerosis, type 2 diabetes mellitus, and arterial hypertension (AH) Timely adequate treatment may prevent the development and progression of these diseases that are main causes of higher death rates Peripheral acting drugs should be preferred for patients at high cardiovascular risk Acarbose is one of these drugs It prevents carbohydrates from being absorbed in the small bowel The results of our use of acarbose have shown its high efficacy Acarbose therapy significantly decreases body weight, postprandial glucose levels, glycated hemoglobin, and blood pressure Acarbose may be used as monotherapy in patients with the metabolic syndrome and mild AH

ReferencesMuscelli Е, Emdin М, Natali A et al. Cardiac responses to insulin in vivo influence of obesity J Clm Endocrinol Metab 1998, 83 2084-90Muscelli Е, Emdin М, Natali A et al. Cardiac responses to insulin in vivo influence of obesity J Clm Endocrinol Metab 1998, 83 2084-90Anderson EA, Hoffinan RP, Balon TW et al. Hypennsulinemia produces both sympathetic neuronal activation and vasodilatation in normal humans J Clin Invest 1991, 876 2246-52Anderson EA, Hoffinan RP, Balon TW et al. Hypennsulinemia produces both sympathetic neuronal activation and vasodilatation in normal humans J Clin Invest 1991, 876 2246-52Lembo G, Napoli R, Capaldo B et al. Abnormal sympathetic overactwity evoked by insulin m the skeletal muscle of patients with essential hypertension J Clin Invest 1992,90 24-9Lembo G, Napoli R, Capaldo B et al. Abnormal sympathetic overactwity evoked by insulin m the skeletal muscle of patients with essential hypertension J Clin Invest 1992,90 24-9Davis SN, Colburn C, Robbins R et al. Evidence that the brain of the conscious dog is insulin sensitive J Clin Invest 1995,95 593-602Davis SN, Colburn C, Robbins R et al. Evidence that the brain of the conscious dog is insulin sensitive J Clin Invest 1995,95 593-602Schwartz MW, Figlewicz DP, Baskin DB et al. Insulin in the bram a hormonal regulator of energy balance EndocrRev 1992, 13 81-113Schwartz MW, Figlewicz DP, Baskin DB et al. Insulin in the bram a hormonal regulator of energy balance EndocrRev 1992, 13 81-113Ferrannmi E, Seghien G, Muscelli E Insulin and the rennin -angeotensm-aldos terone system influence of ACE inhibition J Cardiovasc Pharmacol 1994, 24 (suppl 3) S61-S80Ferrannmi E, Seghien G, Muscelli E Insulin and the rennin -angeotensm-aldos terone system influence of ACE inhibition J Cardiovasc Pharmacol 1994, 24 (suppl 3) S61-S80Wassertheil-Smoller S, Oberman Ą Blaufox MD et al. The trial of antihypertensive ineterventions and management (TAIM) study Final results to blood pressure, cardiovascular risk, and quality of life Am J Hypertens 1992,5 37-44Wassertheil-Smoller S, Oberman Ą Blaufox MD et al. The trial of antihypertensive ineterventions and management (TAIM) study Final results to blood pressure, cardiovascular risk, and quality of life Am J Hypertens 1992,5 37-44Gnmm RH, Grandits GA, Culter JA et al. Relatmnship of quality of life measures— to long-term lifestyle and drug treatment in the treatment of mild hypertension study (TOMHS) Arch Intem Med 1997, 157 638-48Gnmm RH, Grandits GA, Culter JA et al. Relatmnship of quality of life measures— to long-term lifestyle and drug treatment in the treatment of mild hypertension study (TOMHS) Arch Intem Med 1997, 157 638-48Chiasson J et al. The STOP-NIDDM tnal An international study on efficacy of an a-glucosidase inhibitor to prevent type 2 diabetes in a population with IGT Diabetes Care 1998, 21 1720-5Chiasson J et al. The STOP-NIDDM tnal An international study on efficacy of an a-glucosidase inhibitor to prevent type 2 diabetes in a population with IGT Diabetes Care 1998, 21 1720-5

The authors declare that there are no conflicts of interest present.